Filter your results
- 2
- 2
- 4
- 4
- 1
- 1
- 1
- 1
- 4
- 3
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 4
- 3
- 3
- 3
- 2
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
sorted by
|
|
MARCKS protein overexpression in inflammatory breast cancerOncotarget, 2017, 8, pp.6246 - 6257. ⟨10.18632/oncotarget.14057⟩
Journal articles
hal-01787705v1
|
||
|
MARCKS as a Potential Therapeutic Target in Inflammatory Breast CancerCells, 2022, 11 (18), pp.2926. ⟨10.3390/cells11182926⟩
Journal articles
hal-03958360v1
|
||
|
Inflammatory breast cancer in 210�patients: A retrospective study on epidemiological, anatomo‑clinical features and therapeutic resultsMolecular and Clinical Oncology, 2018, 10 (2), pp.223-230. ⟨10.3892/mco.2018.1773⟩
Journal articles
hal-02530356v1
|
||
|
Leptin decreases BC cell susceptibility to NK lysis via PGC1A pathwayEndocrine Connections, 2020, 9 (6), pp.578-586. ⟨10.1530/EC-20-0109⟩
Journal articles
hal-03093782v1
|